NCT06268015 - Botensilimab and Balstilimab Optimization in Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

Botensilimab

75 mg IV every 6 weeks for up to 4 doses

DRUG

Balstilimab

240 mg IV every 2 weeks

DRUG

Oxaliplatin

85 mg/m2 IV every 2 weeks

DRUG

Leucovorin

400 mg/m2 IV every 2 weeks

DRUG

Fluorouracil

400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks

DRUG

Bevacizumab

5 mg/kg IV every 2 weeks

DRUG

Panitumumab

6 mg/kg IV every 2 weeks

Trial Locations (1)

RECRUITING

Duke University, Durham